Entry Point Capital, LLC Ultragenyx Pharmaceutical Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 2,531 shares of RARE stock, worth $127,638. This represents 0.15% of its overall portfolio holdings.
Number of Shares
2,531
Previous 274
823.72%
Holding current value
$127,638
Previous $12.8 Million
713.13%
% of portfolio
0.15%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding RARE
# of Institutions
292Shares Held
88.4MCall Options Held
535KPut Options Held
198K-
Vanguard Group Inc Valley Forge, PA9.78MShares$493 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$283 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.35MShares$270 Million0.68% of portfolio
-
Wellington Management Group LLP Boston, MA4.56MShares$230 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY3.26MShares$164 Million2.24% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.53B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...